logo-loader
viewAeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals raises funds

AEOL 10150 is being developed with funding from the US Department of Health and Human Services as a medical countermeasure against nuclear and chemical weapons, as well as a treatment for pulmonary fibrosis.

DollarRace.jpg
The issued shares come with warrants attached

Aeolus Pharmaceuticals (OTCBB:AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, is to raise US$6.75mln through a private placement.

Both existing and new investors in the company will be acquiring the shares, including entities associated with BVF Partners, a leading life sciences investment firm, which manages the Biotechnology Value Fund family of funds (BVF). 

Aeolus intends to use the funds from the share issue for general corporate and working capital purposes, including the development of AEOL 10150 as a medical counter-measure for the pulmonary effects of acute radiation syndrome, under the company's development contract with the Biomedical Advanced Research and Development Authority (BARDA).

In addition, the company intends to use the proceeds to pursue human clinical trials with AEOL 10150 in Idiopathic pulmonary fibrosis and radiation oncology and the completion of pre-clinical development of AEOL 20415 for infectious diseases and AEOL 11114B for Parkinson's disease.

The new shares have been issued at 22 cents a share, four cents below Friday's closing share price.

Quick facts: Aeolus Pharmaceuticals, Inc.

Price: 0.0018 USD

OTCMKTS:AOLS
Market: PINK
Market Cap: $273.75 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Great Bear Resources sees more impressive results from their...

Great Bear Resources (CVE: GBR) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver with the latest results from their large drill program on the Dix Project in Red Lake, Ontario. Taylor telling Proactive they have expanded the shallow high-grade gold at the LP fault...

18 hours, 53 minutes ago

2 min read